Dr Ngozi Okonjo-Iweala, Gavi Board Chair, and Dr Seth Berkley, Gavi CEO, present Dr Cyrus Poonawalla with the inaugural Vaccine Hero award at Gavi's mid-term review in Abu Dhabi. Credit: Gavi/2018/Oscar Saykens.
ABU DHABI, 10 December 2018 - Dr Cyrus Poonawalla, Founder of Serum Institute of India (SII) and Chairman of Poonawalla Group, has been given the first ever Vaccine Hero award by Gavi, the Vaccine Alliance.
The Vaccine Hero award was inaugurated to celebrate global figures whose dedication to the Vaccine Alliance's mission has played a key role in helping Gavi and its partners to protect hundreds of millions of children across the world.
"Since Gavi's inception Cyrus has been a steadfast supporter of Gavi's mission," said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. "Under his leadership Serum has become the largest supplier of vaccines to the developing world, protecting hundreds of millions of children in the world's poorest countries against killer diseases like measles, diphtheria and meningitis. Gavi simply would not have had the impact we've had without them. He is a worthy winner of this inaugural Vaccine Hero award."
"I am truly humbled to receive this recognition for the humanitarian work that we have been doing at Serum Institute for the last five decades," said Dr Cyrus Poonawalla. "it is recognition such as today's that gives me and my team the strength to commit and continue the humanitarian work by making available immunobiologicals and vaccines at the most affordable prices to support the great efforts made by Gavi and other UN Agencies worldwide, especially now for much needed newer vaccines, such as Pneumonia, Rotavirus, Meningitis, HPV and Dengue."
Dr. Cyrus Poonawalla founded Serum Institute of India in 1966 and built it into the world's largest vaccine manufacturer by volume, supplying more than one billion doses of vaccines per year to children in 170 countries around the world at affordable prices.
SII now supplies 40% of the vaccines funded by Gavi. Over the Alliance's 2016-2020 strategic period, SII will provide more than half a billion doses for Gavi-supported vaccine programmes protecting children against nine diseases - measles, rubella, meningitis A, rotavirus and, through pentavalent vaccine, diphtheria, pertussis, tetanus, Haemophilus influenza type B and hepatitis B. So far SII has distributed more than 18 billion doses of different vaccines and an estimated 25 million lives have been saved because of these vaccines.
The award was presented at a ceremony in Abu Dhabi as part of Gavi's mid-term review, a high-level conference celebrating Gavi's progress and impact in the world's poorest countries. By the end of 2018, Gavi will have contributed to the immunization of 700 million people and the prevention of more than 10 million future deaths. This has contributed to acceleration in the decline of global under-five mortality rates and brought wider impact beyond immunization.
Dr Seth Berkley, Gavi CEO, presents Dr Cyrus Poonawalla with the inaugural Vaccine Hero award at Gavi's mid-term review in Abu Dhabi.
About Gavi, the Vaccine Alliance
Gavi, the Vaccine Alliance is a public-private partnership committed to saving children's lives and protecting people's health by increasing equitable use of vaccines in lower-income countries. The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. Gavi uses innovative finance mechanisms, including co-financing by recipient countries, to secure sustainable funding and adequate supply of quality vaccines. Since 2000, Gavi has contributed to the immunisation of nearly 700 million children and the prevention of 10 million future deaths.
Source - Gavi - The Vaccine Alliance
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
SII CEO Adar Poonawalla & Director Prakash Kumar Singh call on Hon'ble President of India Smt. Droupadi Murmu
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.